SEC-sourced researchBeta

DNLI

Denali Therapeutics Inc.

US markets

Data passport

CIK: 0001714899
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Sep 9, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 6:01 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

DNLI · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	330,531,000.0000	Feb 26, 2026
December 2024	0.0000	Feb 26, 2026
December 2025	0.0000	Feb 26, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	0.0000	-512,540,000.0000	-412,600,000.0000	1,144,854,000.0000	131,093,000.0000	Feb 26, 2026
December 2024	0.0000	-422,773,000.0000	-347,694,000.0000	1,374,180,000.0000	144,496,000.0000	Feb 26, 2026
December 2023	330,531,000.0000	-145,224,000.0000	-357,991,000.0000	—	—	Feb 26, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$0	December 2025	Feb 26, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$0	December 2024	Feb 26, 2026	10-K
Net incomeNetIncomeLoss	-$512.54M	December 2025	Feb 26, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$412.6M	December 2025	Feb 26, 2026	10-K
Total assetsAssets	$1.14B	December 2025	Feb 26, 2026	10-K
Total liabilitiesLiabilities	$131.09M	December 2025	Feb 26, 2026	10-K

New filings

Explore methodology ↗